Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Bio-Gene Technology Ltd. ( (AU:BGT) ) just unveiled an announcement.
Bio-Gene Technology Limited announced the results of its 2025 Share Purchase Plan (SPP), raising $338,500 through the issuance of 14,717,362 fully paid ordinary shares. This, combined with a previous placement, brings the total capital raised to $2.45 million. The funds will support various initiatives, including Flavocide® regulatory studies, Qcide® scale-up, product development, and commercial partnerships. The SPP shares will be issued on 3 June 2025, with trading expected to commence on 4 June 2025, and they will rank equally with existing ordinary shares.
More about Bio-Gene Technology Ltd.
Bio-Gene Technology Limited is an Australian company specializing in the development of novel bio-insecticides aimed at addressing global challenges such as insecticide resistance and toxicity. The company’s unique products, based on naturally occurring compounds, are designed to control pests with minimal impact on human health and the environment. Bio-Gene’s products have applications in public health, crop protection, grain storage, and consumer use, providing effective and safe pest management solutions.
Average Trading Volume: 166,480
Technical Sentiment Signal: Sell
Current Market Cap: A$5.54M
Find detailed analytics on BGT stock on TipRanks’ Stock Analysis page.